Top Emerging Trends Of D-dimer Testing Market Progress Forecast 2027

Posted by Mrudula Karmarkar on January 17th, 2022

The global D-dimer testing market size is expected to reach USD 1.7 billion by 2027, expanding at a CAGR of 4.3%, according to a new report by Grand View Research, Inc. Technological advancements in D-dimer testing have resulted in the development of a wide range of products that have allowed healthcare professionals to offer suitable emergency assistance to patients. The concept of automation in D-dimer testing has provided rapid, less labor-intensive, and user-friendly diagnostic strategies, which is expected to drive the market in the near future.

The commercially available assays often have differences in their antibody specificity as D-dimer antibodies also detect Fibrin Degradation Products (FDPs), leading to incorrect results. To address this issue, Advanced ImmunoChemical, Inc. has developed two monoclonal antibodies, which are used to design one-step immunoassay specific for both FDP and D-dimer. Thus, the development of improved immunoassays that equally detect all FDPs is expected to boost the market growth.

Extensive research for the determination of new D-dimer threshold values for a specific population set prevents the usage of Computed Tomography Pulmonary Angiography (CTPA). This is beneficial as the elimination of CTPA leads to low radiation exposure, which, in turn, increases the demand for the test. To demonstrate this, a group of researchers from Japan determined new elevated D-dimer threshold values for the diagnosis of pulmonary embolism in the Japanese population. Such studies are expected to favor market growth.

A paradigm shift towards the demand for next-generation point-of-care D-dimer testing has driven the market. This is because the implementation of POC solutions significantly reduces waiting time, minimizes the length of patient stay, enables faster diagnosis, and results in improved patient experience. The resounding benefits gained from these solutions in POC settings are considered to boost the growth of the market for D-dimer testing. A rise in the incidence rate of Venous Thromboembolism (VTE) coupled with various pulmonary and cardiovascular diseases that cause life-threatening issues due to blood clot formation is increasing the demand for D-dimer testing.

To Request Sample Copy of this report, click the link:

https://www.grandviewresearch.com/industry-analysis/d-dimer-market/request/rs1

As per estimates of the Centers for Disease Control and Prevention (CDC), around 900,000 people are affected with VTE each year and nearly 60,000-100,000 Americans die due to VTE in the U.S. The advent of aptamers that can reduce the use of antibodies for D-dimer testing is proven to be a cost-effective and long-lasting approach in D-dimer testing. Aptamers are also affordable, stable, and faster to produce as well as possess a longer shelf life as compared to antibodies, thus creating lucrative opportunities for market growth. For instance, aptamers provided by Ayass Bioscience, LLC are observed to be useful in homogeneous assays and manual POC agglutination tests.

D-dimer Testing Market Report Highlights

• Reagents and consumables accounted for the largest revenue share in 2020 owing to the wide availability and frequent usage of reagents in the market space
• Presence of blocking agents that reduce the interferences from heterophilic antibodies to increase the efficiency of immunoassays boost the reagents and consumables segment
• Shorter turnaround times, ease of use, and generation of gold-standard quality results are among the few factors that lead to a lucrative growth of point-of-care testing
• Enzyme-linked Immunosorbent Assays (ELISA) held the largest revenue share because microplate ELISA is considered as a reference method due to its high sensitivity for coagulation markers
• Deep Vein Thrombosis (DVT) dominated the revenue share in 2020 as this test is a reliable method and is used as a routine screening test for DVT
• The hospitals\' segment accounted for the maximum revenue share in 2020
• This is attributive to a rise in the rate of pulmonary embolism cases in hospitalized patients, which results in high adoption of the test in hospitals
• Asia Pacific is expected to witness a lucrative CAGR due to a rise in the funding initiatives that support research studies related to the usage of these assays in various diseases
• The National Natural Science Foundation of China and the Fundamental Research Funds for the Central Universities are among the few agencies involved in funding research studies in China
• Key companies operating in the market have undertaken several growth initiatives to expand their product portfolio
• For instance, in February 2020, HORIBA introduced the Yumizen D-Dimer reagent kit for measurement and reference exclusion testing for DVT and pulmonary embolism.

Key players are adopting strategic growth initiatives to reinforce their product offerings and maintain a competitive edge in the market for D-dimer testing. In addition, key players are involved in the development of sensitive as well as automated hemostasis markers for the expansion of market potential. For instance, in April 2020, Ortho Clinical Diagnostics, a U.S.-based company, launched its D-Dimer assay in collaboration with Diazyme Laboratories, Inc. This new assay is one of the latest product of MicroTip Partnership Assay Program of Ortho Clinical, which allow the company to provide high value, flexible, quick, and esoteric testing solutions. This product launch expanded the company’s expertise to offer innovative assay to its customers. Some of the prominent players in the D-dimer testing market include:

• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Siemen Healthineers
• Abbott
• biomérieux SA
• WERFEN
• HORIBA, Ltd.
• Quidel Corporation
• Diazyme Laboratories, Inc.
• Biomedica Diagnostics
• Sekisui Diagnostics